Abstract
In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement inhibitors, neonatal Fc receptor targeting agents, and B cell interfering drugs, focusing on benefit and danger. In the second section of the review, several related adverse events of immunotherapy, including MGonset, are debated.
Lingua originale | English |
---|---|
pagine (da-a) | 1367-1375 |
Numero di pagine | 9 |
Rivista | Neurological Sciences |
Volume | 42 |
DOI | |
Stato di pubblicazione | Pubblicato - 2021 |
Keywords
- Checkpoint inhibitors
- Emerging therapy
- Immunotherapy
- Refractory myasthenia gravis